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Familial dilated cardiomyopathy: 
another risk factor for anthracycline-
induced cardiotoxicity?
9
Maarten P. van den Berg
Karin Y. van Spaendonck-Zwarts
Dirk J. van Veldhuisen
Jourik A. Gietema
 Aleida Postma
J. Peter van Tintelen 
European Journal of Heart Failure 2010; 12: 1297-1299
Spaendonck.indd   203 21-01-14   09:00
204
Spaendonck.indd   204 21-01-14   09:00
205
BACKGROUND
Since their introduction in the late 1960s, anthracyclines such as daunorubicin and doxorubicin 
have been successfully used in the treatment of  a wide variety of  tumours. However, their use 
is limited by the occurrence of  cardiotoxicity, which may result in left ventricular (LV) dysfunc-
tion/dilated cardiomyopathy (DCM) and eventually heart failure.1,2 Several risk factors have 
been identified for anthracycline-induced cardiotoxicity: the most important one is the total 
cumulative dose of  anthracycline given, with a cumulative dose of  daunorubicin and doxoru-
bicin up to 450 mg/m2 being considered relatively safe.1,2 However, in some patients, LV dysfunc-
tion/DCM develops after anthracycline treatment which is not fully explicable in terms of  the 
established risk factors, suggesting that other factors, probably including genetic ones, play a role. 
AIMS
Here, we report two patients who were treated for cancer and who later developed DCM; a 
genetic predisposition for DCM is believed to have played a role. 
METHODS
Among other patients with possible hereditary cardiac disorders, we see at the cardiogenetics 
outpatient clinic of  the University Medical Centre Groningen patients with idiopathic DCM. 
As part of  routine procedures, the patients’ clinical characteristics are collected, pedigrees are 
constructed, full family histories are obtained, and family members at risk are invited for 
pre-symptomatic (‘cascade’) screening using family letters.3,4 Dilated cardiomyopathy is diag-
nosed if  there is both a reduced systolic function (ejection fraction <0.45) and dilation of  the 
LV (end-diastolic dimension >117% of  the predicted value corrected for body surface area 
and age). If  only one of  these criteria is fulfilled, the case is labelled mild DCM. In addition, 
identifiable causes like severe hypertension, coronary artery disease, and systemic diseases 
should have been excluded.5,6 Familial DCM (fDCM) is diagnosed if  two or more affected 
individuals are present in a family or if  the patient with DCM has a first-degree relative who 
died suddenly before the age of  35 years.6 All patients are asked to give permission for their 
clinical data to be used for scientific research. 
Genomic DNA is isolated from blood samples obtained from the index patients, using DNA 
samples from 300 ethnically matched control alleles. As part of  our routine clinical care, DNA 
analysis is performed for the following major DCM-related genes: lamin A/C (LMNA), 
cardiac troponin T (TNNT2), and β-myosin heavy chain (MYH7), using established techniques.7
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RESULTS
Patient A had had acute lymphoid leukaemia at the age of  9 years for which he received several 
non-cardiotoxic agents. At the age of  12 years, he had a relapse which was treated with dauno-
rubicin (cumulative dose 175 mg/m2) and allogenic stem cell transplantation (including total 
body radiation (12 Gy)). At the age of  17 years, he presented with reduced exercise tolerance 
and LV dysfunction, which at that time was attributed to the earlier anti-cancer treatment. He 
is now 30 years old and he is in New York Heart Association functional class II. Left ventricular 
ejection fraction and LV end-diastolic dimension are at present 0.40 and 28 mm/m2, respec-
tively. As part of  a research project on the late effects of  childhood cancer treatment, his 
24-year-old brother recently participated as a ‘healthy’ sibling control and was found to have 
an LV ejection fraction of  0.42 and an LV end-diastolic dimension of  27 mm/m2. After this 
unexpected finding, the attending oncologist considered the possibility of  fDCM and referred 
the two brothers to our cardiogenetics outpatient clinic for further analysis. The family history 
revealed that their father had been diagnosed with heart failure due to idiopathic DCM in a 
regional hospital 3 years earlier at the age of  56 years. Since both Patient A’s brother and father 
were affected with idiopathic (mild) DCM, fDCM was considered in this family (Figure 1A). 
However, DNA analysis of  LMNA, MYH7, and TNNT2 did not reveal an underlying muta-
tion in this family.
Patient B had had a neuroblastoma at the age of  2 years for which he had been treated with 
cyclophosphamide and doxorubicin (cumulative dose 420 mg/m2). At the age of  16 years, he 
presented with heart failure due to severe LV dysfunction, which at that time was attributed to 
the chemotherapy. He is now 29 years old and although he has relatively mild symptoms, the 
LV function is severely depressed (ejection fraction 0.25) and the LV is dilated (LV end-diastolic 
dimension 31 mm/m2). At a recent routine follow-up, the patient told the attending oncologist 
that his father had just been diagnosed with ‘heart failure’ in a regional hospital. The possibility 
of  fDCM was considered and the patient was referred to our cardiogenetics outpatient clinic 
for further analysis. The review of  the available cardiac data from Patient B’s father indicated 
that he had been diagnosed with heart failure due to idiopathic DCM at the age of  57 years. 
Two family members, Patient B’s brother and a paternal uncle, responded to the family letters 
and were investigated. The uncle was 66 years old and asymptomatic but echocardiography 
revealed mild DCM. The brother was 24 years old, asymptomatic but echocardiography also 
revealed mild DCM. Since Patient B’s father, uncle, and brother were affected with (mild) 
idiopathic DCM, fDCM was also considered likely in Family B (Figure 1B). Two muta-
tions in MYH7 were identified in Patient B and his affected family members: c.1633G > A 
(p.Asp545Asn) in exon 16 and c.2863G > A (p.Asp955Asn) in exon 23. Both mutations have 
been published previously8 and segregation analysis demonstrated that these two MYH7 muta-
tions were on the same allele (in cis) that also segregated with the disease in this family. 
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CONCLUSION
Our two cases suggest the presence of  a previously unrecognized risk factor for the develop-
ment of  anthracycline-induced cardiotoxicity, namely a genetic/familial predisposition for 
DCM. Patient A developed DCM at a young age, despite having received only a low dose of  
daunorubicin.1,2,9 Even though other factors may have contributed to the anthracycline cardiotox-
icity, in particular radiation therapy and young age, it remains difficult to accept that the anti-
cancer treatment was solely responsible. Rather, it is conceivable that Patient A is a carrier of  a 
yet unidentified mutation causing DCM in his family and that this contributed to the develop-
ment of  his DCM. In the case of  Patient B, a proven carrier of  DCM-causing mutations, it is 
also likely that his genetic predisposition for DCM contributed to its actual development. 
Our study not only provides new insight for the oncologist but also for the cardiogeneticist 
dealing with DCM patients and their families. fDCM is characterized by variable penetrance,10 
implying that even within a single family, proven disease-causing mutation carriers may live into 
senescence without showing any clinical signs of  DCM, whereas other mutation carriers may 
experience the early onset of  disease and progression to heart failure. Variable penetrance was 
also evident in our two families, the two fathers presenting with DCM at a later age than their 
sons. The phenomenon of  variable penetrance suggests that in addition to the specific genetic 
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Figure 1: Pedigree of the family of Patient A (left panel) and Patient B (right panel). 
Square and round symbols depict male and female, respectively. Filled symbols depict family members 
with (mild) dilated cardiomyopathy. Arrows indicate the cancer patients.
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predisposition, other factors, including environmental ones, must also play a role in the patho-
genesis of  fDCM. Our two cases represent probable examples of  an environmental factor, 
namely anti-cancer treatment with known cardiotoxic agents. Our study thus provides evidence 
for a ‘gene–environment interaction’ with regard to the development of  DCM after anti-cancer 
treatment, with an environmental factor (cardiotoxic treatment) eliciting early-onset and/or 
severe DCM in the setting of  a genetic predisposition for DCM. 
In terms of  practicality, we recommend careful evaluation of  the family history for fDCM 
before treating a cancer patient with cardiotoxic agents. And conversely, clinicians should be 
aware of  the possibility that disproportionate LV dilatation and systolic dysfunction after 
chemotherapy may be a manifestation of  fDCM. 
In conclusion, our study suggests that a family history of  DCM is another risk factor for the 
development of  anthracycline-induced cardiotoxicity. A way to further explore this concept 
would be to perform genetic research (investigation of  family members and DNA analysis) in 
patients with disproportionate LV dilatation and systolic dysfunction after chemotherapy. 
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